Retrospective Survey of Hyperkalemia in Hemodialysis

NCT ID: NCT05020717

Last Updated: 2021-08-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-09-30

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aim to describe hyperkalemia clinical burden and investigate the risk factors associated with the burden on HD facility level.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is an observational survey study. We estimate 300 hemodialysis (HD) centres will be enrolled in the study. Summarized data on serum potassium (sK) after long interdialytic interval (LIDI), facility practice pattern and patient characteristics which may be related with sK management, and death records information including number of deaths for each centre will be collected. All the data collected and analysed are on HD facility level, not on patient-level. We are aiming to describe hyperkalemia clinical burden and investigate the risk factors associated with the burden on HD facility level. Association between sK management and long-term outcome will also be explored.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemodialysis Complication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

For HD centers:

* ≥ 100 patients under MHD within 3 years prior the study initiation
* Willing to participate in the study
* Have routine blood collection after LIDI
* Have death records

For HD patients:

• On chronic HD for ≥ 3 months

Exclusion Criteria

* Blood test on other days than those after LIDI
* Unable to provide detailed data required by study protocol
* Being unable to comply with study-specified procedure
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role collaborator

Peking University People's Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Li Zuo

Head of the Nephrology Department

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Li Zuo

Role: PRINCIPAL_INVESTIGATOR

Peking University People's Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Peking University People's Hospital

Beijing, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Li Zuo

Role: CONTACT

+86(10)88324008

Xinju Zhao

Role: CONTACT

+86(10)88325018

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Baoguo Jiang

Role: primary

+86(10)88324008

Li Zuo

Role: backup

+86(10)88324008

References

Explore related publications, articles, or registry entries linked to this study.

Xinju Z, Changying X, Hong L, Guisen L, Ping Z, Caili W, Zuying X, Gang X, Rong W, Rongshan L, Aili J, Hongli J, Jianxin W, Xiaoling W, Jing Y, Li Y, Pei W, Rui Z, Yunhua L, Huimin L, Jinsheng X, Menghua C, Yinhui L, Qinkai C, Zhongfei Y, Yan Z, Hong L, Wenbo H, Chen L, Zhaohui N, Lingling G, Li Z. Prevalence, practice pattern, and mortality of hyperkalemia in Chinese patients undergoing hemodialysis in the visualize HD study. Sci Rep. 2025 Jul 1;15(1):22405. doi: 10.1038/s41598-025-92609-1.

Reference Type DERIVED
PMID: 40596462 (View on PubMed)

Zhao X, Zuo L. Multicentre, observational, retrospective cohort of hyperkalaemia burden at haemodialysis facility-level in China: the Visualize-HD study protocol. BMJ Open. 2023 Sep 21;13(9):e066394. doi: 10.1136/bmjopen-2022-066394.

Reference Type DERIVED
PMID: 37734899 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20-20591

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Chinese Cohort Study of Chronic Kidney Disease
NCT03041987 ACTIVE_NOT_RECRUITING